Naoya Miyashita

Dr. Naoya Miyashita

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NMNaoya Miyashita
Naoya Miyashita
ASAkira Saito
Akira Saito
Fibroblasts constitute a ubiquitous mesenchymal cell type and produce the extracellular matrix (ECM) of connective tissue, thereby providing the structural basis of various organs. Fibroblasts display differential transcriptional patterns unique to the organ of their origin and they can be activated by common stimuli such as transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) signaling. Cancer-associated fibroblasts (CAFs) reside in the cancer tissue and contribute to cancer progression by influencing cancer cell growth, invasion, angiogenesis and tumor immunity. CAFs impact on the tumor microenvironment by remodeling the ECM and secreting soluble factors such as chemokines and growth factors. Differential expression patterns of molecular markers suggest heterogeneous features of CAFs in terms of their function, pathogenic role and cellular origin. Recent studies elucidated the bimodal action of CAFs on cancer progression and suggest a subgroup of CAFs with tumor-suppressive effects. This review attempts to describe cellular features of colorectal CAFs with an emphasis on their heterogeneity and functional diversity.

30 August 2022 in Cancer Science
Verified
Journal Article
Open access
KMKazuko Miyakawa
Kazuko Miyakawa
NMNaoya Miyashita
Naoya Miyashita
MHMasafumi Horie
Masafumi Horie
YTYasuhiro Terasaki
Yasuhiro Terasaki
HTHidenori Tanaka
Hidenori Tanaka
ASAkira Saito
Akira Saito
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with dismal prognosis. Recently, molecular subtypes of SCLC have been defined by the expression status of ASCL1, NEUROD1, YAP1, and POU2F3 transcription regulators. ASCL1 is essential for neuroendocrine differentiation and is expressed in the majority of SCLC. Although previous studies investigated ASCL1 target genes in SCLC cells, ASCL1‐mediated regulation of miRNAs and its relationship to molecular subtypes remain poorly explored. Here, we performed genome‐wide profiling of chromatin modifications (H3K27me3, H3K4me3, and H3K27ac) by CUT&Tag assay and ASCL1 knockdown followed by RNA sequencing and miRNA array analyses in SCLC cells. ASCL1 could preferentially regulate genes associated with super‐enhancers (SEs) defined by enrichment of H3K27ac marking. Moreover, ASCL1 positively regulated several SE‐associated miRNAs, such as miR‐7, miR‐375, miR‐200b‐3p, and miR‐429, leading to repression of their targets, whereas ASCL1 suppressed miR‐455‐3p, an abundant miRNA in other molecular subtypes. We further elucidated unique patterns of SE‐associated miRNAs in different SCLC molecular subtypes, highlighting subtype‐specific miRNA networks with functional relevance. Notably, we found apparent de‐repression of common target genes of different miRNAs following ASCL1 knockdown, suggesting combinatorial action of multiple miRNAs underlying molecular heterogeneity of SCLC (e.g., co‐targeting of YAP1 by miR‐9 and miR‐375). Our comprehensive analyses provide novel insights into SCLC pathogenesis and a clue to understanding subtype‐dependent phenotypic differences.

15 March 2023 in Cancer Science
Verified
Journal Article
Open access
MHMasafumi Horie
Masafumi Horie
HTHidenori Tanaka
Hidenori Tanaka
MSMasami Suzuki
Masami Suzuki
YSYoshihiko Sato
Yoshihiko Sato
STSo Takata
So Takata
SYShinichi Yachida
Shinichi Yachida
Neuroendocrine carcinoma (NEC) is a highly aggressive subtype of the neuroendocrine tumor with an extremely poor prognosis. We have previously conducted a comprehensive genomic analysis of over 100 cases of NEC of the gastrointestinal system (GIS‐NEC) and unraveled its unique and organ‐specific genomic drivers. However, the epigenomic features of GIS‐NEC remain unexplored. In this study, we have described the epigenomic landscape of GIS‐NEC and small cell lung carcinoma (SCLC) by integrating motif enrichment analysis from the assay of transposase‐accessible chromatin sequencing (ATAC‐seq) and enhancer profiling from a novel cleavage under targets and tagmentation (CUT&Tag) assay for H3K27ac and identified ELF3 as one of the super‐enhancer–related transcriptional factors in NEC. By combining CUT&Tag and knockdown RNA sequencing for ELF3, we uncovered the transcriptional network regulated by ELF3 and defined its distinctive gene signature, including AURKA, CDC25B, CLDN4, ITGB6, and YWAHB. Furthermore, a loss‐of‐function assay revealed that ELF3 depletion led to poor cell viability. Finally, using gene expression of clinical samples, we successfully divided GIS‐NEC patients into two subgroups according to the ELF3 signature and demonstrated that tumor‐promoting pathways were activated in the ELF3 signature–high group. Our findings highlight the transcriptional regulation of ELF3 as an oncogenic transcription factor and its tumor‐promoting properties in NEC.

1 October 2020 in Cancer Letters
Verified
Journal Article
Closed access
NMNaoya Miyashita
Naoya Miyashita
MHMasafumi Horie
Masafumi Horie
YMYu Mikami
Yu Mikami
HUHirokazu Urushiyama
Hirokazu Urushiyama
KFKensuke Fukuda
Kensuke Fukuda
ASAkira Saito
Akira Saito

6 October 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
TETakayoshi Enokido
Takayoshi Enokido
MHMasafumi Horie
Masafumi Horie
SYSeiko Yoshino
Seiko Yoshino
HSHiroshi I. Suzuki
Hiroshi I. Suzuki
RMRei Matsuki
Rei Matsuki
NMNaoya Miyashita
Naoya Miyashita
Achaete-scute family bHLH transcription factor 1 (ASCL1) is a master transcription factor involved in neuroendocrine differentiation. ASCL1 is expressed in approximately 10% of lung adenocarcinomas (LUAD) and exerts tumor-promoting effects. Here, we explored miRNA profiles in ASCL1-positive LUADs and identified several miRNAs closely associated with ASCL1 expression, including miR-375, miR-95–3p/miR-95–5p, miR-124–3p, and members of the miR-17∼92 family. Similar to small cell lung cancer, Yes1 associated transcriptional regulator (YAP1), a representative miR-375 target gene, was suppressed in ASCL1-positive LUADs. ASCL1 knockdown followed by miRNA profiling in a cell culture model further revealed that ASCL1 positively regulates miR-124–3p and members of the miR-17∼92 family. Integrative transcriptomic analyses identified ZFP36 ring finger protein like 1 (ZFP36L1) as a target gene of miR-124–3p, and IHC studies demonstrated that ASCL1-positive LUADs are associated with low ZFP36L1 protein levels. Cell culture studies showed that ectopic ZFP36L1 expression inhibits cell proliferation, survival, and cell-cycle progression. Moreover, ZFP36L1 negatively regulated several genes including E2F transcription factor 1 (E2F1) and snail family transcriptional repressor 1 (SNAI1). In conclusion, our study revealed that suppression of ZFP36L1 via ASCL1-regulated miR-124–3p could modulate gene expression, providing evidence that ASCL1-mediated regulation of miRNAs shapes molecular features of ASCL1-positive LUADs. Implications: Our study revealed unique miRNA profiles of ASCL1-positive LUADs and identified ASCL1-regulated miRNAs with functional relevance.

1 August 2025 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
TITaro Ishimori
Taro Ishimori
MSMinako Saito
Minako Saito
MYMasaaki Yuki
Masaaki Yuki
MHMototaka Hattori
Mototaka Hattori
MSMasahiro Shuzui
Masahiro Shuzui
AMAkihisa Mitani
Akihisa Mitani
Our study is the first to elucidate the protective role of SIRT3 in the pathogenesis of COPD by modulating inflammatory responses and apoptosis. We have demonstrated that SIRT3 knockout mice spontaneously develop emphysema, and SIRT3 overexpression reduced elastase and LPS-induced emphysematous changes. In vitro studies have shown that SIRT3 deficiency leads to increased inflammation, oxidative stress, and apoptosis in airway and alveolar epithelium, contributing to the formation and exacerbation of emphysema.